Edition:
India

KemPharm Inc (KMPH.OQ)

KMPH.OQ on NASDAQ Stock Exchange Global Market

5.15USD
13 Jul 2018
Change (% chg)

$-0.35 (-6.36%)
Prev Close
$5.50
Open
$5.45
Day's High
$5.45
Day's Low
$5.05
Volume
26,428
Avg. Vol
20,985
52-wk High
$8.35
52-wk Low
$2.45

Chart for

About

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is... (more)

Overall

Beta: --
Market Cap(Mil.): $55.33
Shares Outstanding(Mil.): 14.66
Dividend: --
Yield (%): --

Financials

BRIEF-Kempharm Announces Positive Topline Results From KP415 Pharmacokinetic Study In Children And Adolescents With ADHD

* KEMPHARM ANNOUNCES POSITIVE TOPLINE RESULTS FROM KP415 PHARMACOKINETIC STUDY IN CHILDREN AND ADOLESCENTS WITH ADHD

20 Mar 2018

KemPharm's opioid painkiller gets FDA approval, shares soar

KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain, sending the shares of the drugmaker up as much as 36 percent in late afternoon trading.

24 Feb 2018

UPDATE 1-KemPharm's opioid painkiller gets FDA approval, shares soar

Feb 23 KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain, sending the shares of the drugmaker up as much as 36 percent in late afternoon trading.

24 Feb 2018

BRIEF-Kempharm Announces FDA Approval Of Apadaz

* KEMPHARM SAYS U.S. FDA APPROVED NDA FOR APADAZ FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE OPIOID ANALGESIC

24 Feb 2018

FDA approves KemPharm's opioid painkiller

Feb 23 KemPharm Inc said on Friday the U.S. Food and Drug Administration approved its opioid painkiller Apadaz for the short-term management of acute pain. The company resubmitted the drug's marketing application for review in September last year after appealing against the drug regulator's decision to reject it in 2016.

24 Feb 2018

Earnings vs. Estimates